Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent

A method of treating a subgroup of subjects from a population of subjects having ovarian cancer, prostate cancer, glioblastoma, or breast cancer comprising:

• (i) providing a subject from the population of subjects known to overexpress at least one gene relative to a pre-defined cut-off threshold value which separates a particular disease into a first phenotype that indicates responsiveness to an anti-angiogenic agent and a second phenotype that indicates resistance to the anti-angiogenic agent, wherein the at least one gene is selected from the group consisting of GJB2, MMP13, GFPT2, BICC1, CDH11, MRVI1, PMP22, COL11Al, IGFL2, LUM, NTM, BGN, COL3A1, COL10A1, RAB31, ANGPTL2, PLAU, COL8A1, MIR1245, POLD2, NKD2, FZD1, COPZ2, ITGA5, VGLL3, MMP14, VCAN, THBS2, RUNX2, TIMP3, SFRP2, COL1A2, COL5A2, SERPINF1, KIF26B, TNFAIP6, MMP2, FN1, ALPK2, CTSK, LOXL1, and FAP in a tumor sample from the subject;
• and (ii) administering the anti-angiogenic agent to the subject in an amount sufficient to inhibit angiogenesis in the cancer.